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Abstract 
This study has characterized the repertoire of the anion exchanger (AE) family members expressed within the guinea pig 
organ of Corti, the auditory neuroepithelia. Both AE2 and AE3 cDNAs were present, but AE1 cDNA was not detected. The 
more abundant AE2 was sequenced and its expression characterized in the cochlea. The 3888 base pairs (bp) AE2 sequence, 
compiled from multiple clones, includes 150 bp of upstream non-coding sequence and 3717 bp of open reading frame 
encoding aprotein of 1238 amino acids. Immunoblot of cochlear homogenate r vealed asingle AE2-immunoreactive band of 
Mr 180 kDa. In situ hybridization and immunohistochemical analysis localized AE2 expression to several tissues and cell 
types within the guinea pig inner ear, including superior half of the spiral ligament and within the interdental cells lining the 
spiral limbus. However, AE2 was not clearly detected in the outer hair cells (OHC) of the organ of Corti by either 
immunohistochemistry or in situ hybridization. The results of these studies imply a physiologic role of AE2 in the cochlear 
homeostasis, but do not support its role as a potential 'motor protein' in mediating the in vitro-observed voltage-gated, ATP- 
independent OHC motility. © 1998 Elsevier Science B.V. All rights reserved. 
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1. Introduction 
The outer hair cells (OHC) and the inner hair cells 
(IHC) are the two subtypes of mechanosensory cells 
within the mammalian cochlea. Although, structur- 
ally very similar, several differences have been iden- 
tified between the two cell types that reflect their 
distinct in vivo function. A particular in vitro char- 
acterized OHC trait is its electromotility. Current 
* Corresponding author. Fax: +1 (415) 476-2169; 
E-mail: lalwani@itsa.ucsf.edu 
injection into isolated OHC can change cell length 
up to 4% [1,2]. This contractile or motile response 
is unique to the OHC; it is not observed in the IHC 
or in the hair cells of the vestibular apparatus re- 
sponsible for our sense of balance. The motility is 
Ca 2+ and ATP-independent [3,4], and thus not likely 
to involve conventional motor proteins, such as actin 
and myosin, that have been associated with cell 
movement. The voltage-gated lectromotility, also re- 
ferred to as electromechanical transduction, is postu- 
lated to augment he vibrations of the basilar mem- 
brane immediately beneath the IHC and OHC, and 
thereby to amplify the input signal [2,4-6]. 
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Physiological/biochemical studies investigating this 
contractile apparatus suggest that the putative motor 
protein resides within the OHC plasma membrane. 
The critical experiments supporting this hypothesis 
include demonstration of OHC motility in isolated 
OHC plasma membrane, free from its cytoskeletal 
framework and underlying substructure [7] and its 
persistence, postintracellular t ypsin digestion [8]. 
Furthermore, it is postulated that changes in cell 
length are brought about through voltage-gated con- 
formational changes in an abundant transmembrane 
protein. It is estimated that there exists in each OHC 
approximately 1.2x106 such molecules [7,9,10] 
whose voltage-gated movement, transverse to the 
plane of the membrane, is responsible for the 'gating 
current' that accompanies the OHC motile response. 
It is inferred that the force generated in the lateral 
wall of the plasma membrane needs to be linked with 
the underlying cytoskeletal framework to effect 
change in cell shape. Ultrastructural studies of the 
OHC membrane have demonstrated the presence of 
a lattice-like structure directly beneath the plasma 
membrane. Ultrastructural and molecular analysis 
of the cortical lattice has revealed an architecture 
and components similar to those identified in the 
cytoskeleton of the erythrocyte [11]. Similar to the 
erythrocyte cytoskeleton, the cortical attice includes 
actin and spectrin isoforms [12-14]. The spectrin ac- 
tin complex of the erythrocyte cytoskeleton is linked 
to the band 3 protein or anion exchanger 1 (AE1), 
the major integral plasma membrane protein of the 
erythrocyte, via the linkage proteins, ankyrin I, pro- 
tein 4.2, and protein 4.1. Proteins recognized by anti- 
bodies raised against erythroid AE1 and protein 4.1 
have been detected within the OHC of guinea pigs 
[15] and gerbils [16]. The relevance of these putative 
cytoskeletal components of OHC to its motility 
stems from the recognized importance of actin, spec- 
trin, ankyrin I, protein 4.1 and AE1 to the mechan- 
ical stability of the erythrocyte. 
AE1, an anion exchanger that facilitates exchange 
of CI/HCO3 across the plasma membrane, is one of a 
family of related proteins considered to be an impor- 
tant component in the regulation of intracellular pH 
and volume (for reviews see Kopito [17], Alper [18], 
and Alper et al. [19]). The anion transport function 
of AE1 is inhibited by 4,4'-diisothiocyanostilbene- 
2,2'-disulfonic acid (DIDS), a stilbene disulfonate 
agent that also exerts inhibitory effect upon OHC 
electromotility. These data, taken together, suggest 
the possibility that an AE-like anchor protein could 
link the OHC cytoskeleton to its plasma membrane, 
perhaps to mediate or modulate the contractile re- 
sponse, and so functioning as or contributing to the 
molecular motor in the OHC. 
The AE gene family consists of at least three mem- 
bers, AE1, AE2 and AE3, whose cDNAs have been 
cloned in several species from different issues or cell 
types. AE1 (band 3) was the first of the AE anion 
exchangers to be cloned and characterized [20]. This 
anion carrier is highly abundant in the red cell mem- 
brane, comprising ,~ 25% of total membrane protein, 
and up to 50% of integral membrane protein, and 
present in 1-1.2 million copies per human red cell. 
The role of AE1 in the erythrocyte is to facilitate 
carriage of CO2 away from respiring tissues, and to 
stabilize the cytoskeleton. Genetic deficiency of AE1 
has been associated with autosomal dominant forms 
of spherocytosis [21] and of distal renal tubular 
acidosis [22,23]. 
Other members of the AE gene family have been 
cloned from cDNA libraries probed with AE 1 coding 
sequence under low stringency hybridization. Alter- 
native exon usage has been found to generate multi- 
ple mRNA transcripts from each of the three AE 
anion exchanger genes [24-26]. Physiological roles 
for the polypeptide products of these alternative 
transcripts from the AE2 and AE3 genes remain to 
be determined in intact animals. Outside the red cell, 
AE1 or related protein has been found in acid-secret- 
ing renal intercalated cells, and in cardiac myocytes. 
In contrast, AE2 is widely expressed in epithelial and 
non-epithelial cells, with high levels found in choroid 
plexus and gastric parietal cells [27]. AE3 is expressed 
at highest levels in excitable tissues including neurons 
and muscle, as well as in the gastrointestinal tract. 
Proteolytic leavage studies have defined two ma- 
jor structural domains of AE1 and AE2 [28]. The 
hydrophilic aminoterminal domain of the AE poly- 
peptides is located on the cytosolic side of the mem- 
brane, and interacts with several cytoplasmic pro- 
teins including ankyrin, that links the plasma 
membrane with the underlying membrane skeleton. 
Ankyrin-1 has a binding site for AE1 [29] and for 
bAE3, but not for AE2 [30]. The ion transport func- 
tion of the AE proteins is mediated by their carbox- 
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yl-terminal membrane-spanning domains. Presence 
of the N-terminal domain from the AE polypeptides 
is not required for expression of basal anion ex- 
change activity [17]. The highest degree of sequence 
conservation is in the carboxy-terminal domain, 
while the amino-terminal domain displays greater 
variability. Topography experiments on AE1, togeth- 
er with hydropathy analysis of the deduced polypep- 
tide sequences of all the AE polypeptides, uggest 
that the highly conserved carboxy-terminal domain 
traverses the lipid bilayer 12 or more times. 
An initial step towards assessing a possible role of 
AEs in OHC motility is to identify and characterize 
expression of its family members at the RNA and 
protein level within the OHCs. A candidate gene 
product for the role of OHC motor protein should 
meet several criteria: it should be present within the 
OHC (but not necessarily exclusively), and localized 
along the length of the lateral OHC membranes 
[10,31], likely excluding the apical and basal mem- 
branes since the force is generated longitudinally. 
Such candidate motor proteins could then be char- 
acterized physiologically for their roles in OHC mo- 
tility. 
Due to the limited number of outer hair cells 
present within the auditory neuroepithelia and to 
the relative difficulty of their extraction in an intact 
and, homogeneous form, we have chosen to assess 
their genetic repertoire in a cDNA library derived 
from the entire guinea pig (gp) organ of Corti. This 
library, generated by Wilcox and Fex [32], represents 
one of the richest sources of hair cell cDNA. The 
hair cells represent approximately 5% of the total 
cells within the organ of Corti. This library has 
been used previously by Negrini et al. [33] to isolate 
a novel AE2 cDNA clone. AE2t~ encodes a truncated 
AE2 polypeptide of Mr 89 kDa secondary to deletion 
in the cDNA of 83 bp near the beginning of the 
membrane-spanning domain, and was detected by 
RT-PCR in every tissue examined. The predicted 
89 kDa polypeptide was detected in cochlear homo- 
genate by immunoblot [33], and antibody to the nov- 
el sequence of AE2o~ immunostained stereocilia nd 
the lateral wall of the OHC, as well as stereocilia of 
the IHC [34]. 
In this study, we have screened, at low stringency, 
the organ of Corti cDNA library to detect members 
of the AE gene family. AE2 clones were found to be 
most abundant members of the AE family in the 
library. The complete coding sequence of gp AE2, 
together with flanking regions, was determined. Ex- 
pression of mRNA encoding AE2, but not AE2tx, 
was confirmed in gp organ of Corti by RT-PCR. 
Expression of AE2 polypeptide was characterized in 
cochlear homogenate by immunoblot, and in situ by 
immunohistochemistry and in situ hybridization. The 
results of this study are discussed in the context of 
the hypothesis that an anion exchanger of the AE 
gene family may mediate or contribute to OHC elec- 
tromotility. 
2. Materials and methods 
2.1. Materials 
Plasmids, pMAE1, pMAE2 and pMAE3 were ob- 
tained from R. Kopito (Stanford University). The 
coding sequence of these AE cDNAs were used to 
screen a gp organ of Corti cDNA library obtained 
from E. Wilcox (NIH) [32]. The AE2 antibody raised 
against mouse AE2 1224-1237 [27]. Specificity of this 
antibody for immunocytochemistry has been previ- 
ously characterized in multiple tissues [19,27,35,36]. 
2.2. Methods 
2.2.1. Library screen 
Approximately 10 6 clones from an amplified organ 
of Corti cDNA library were screened with 32p la- 
beled, random primed probe generated from equimo- 
lar amounts of AE 1, AE2 and AE3 full length coding 
sequences. Hybridization (42°C) and post-hybridiza- 
tion washes (45°C at 1 × SSC) were carried out under 
low stringency conditions as described by Church 
and Gilbert [37]. Positive clones were then character- 
ized by restriction digest and sequence analysis of the 
5' and 3' ends of the inserts. 
2.2.2. DNA sequencing and analysis 
Individual clones from the library were sequenced 
using the ABI automated sequencer. T7, SP6, M13 
forward and reverse primers and numerous custom 
made primers were used for sequencing reactions on 
purified plasmids. In addition, RT-PCR products de- 
rived from organ of Corti cDNA using AE2 specific 
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GAGGCAGCACC TACACCGGGGCACGGCAAC AC AAGCTCAGCTGAGCAGGCTGGAGTGGAG 2820 
Glu Ala Ala Pro Thr Pro Gly His GIv Asn Thr Ser Ser AIo Glu Gin Ala GIv Vat Glu 
AGAC£CCAGGGCCAGCCCAACACAGCCC TGCTGTCGTTGGTGCTCATGGCTGGCACCTTC 2880 
Arg Pro Gin Gly Gin Pro Asn Thr AIo Leu Leu Set Leu Val Leu Met AIo GI y Thr Phe 
TTCATTGCC TTCTTCTTGCGAAAATTTAAGAACAGCCGGTTTTTCCC TGGCCGGATCCGG 29q0 
Phe lie AIo Phe Phe Leu Ar'g Lys Phe Lys Asn Set Ar'g Phe Phe Pro Gly Arg Ile Arg 
CGGGTGATTGGGGACTTTGGAGTGCCCATCGCCATCCTCAT£ATGGTG£ TCGTGGATTAC 3000 
Ar 9 Val lie Gly Asp Phe GIv Vat Pro Ile Ala lie Leu Ile Met Val Leu Val Asp Tyr 
AGTATTCAAGACACCTACACGCAGAAGC TGAGTGTGC CCAGTGGATTCTCTGTGACAGCC 3060 
Set Ile Gin Asp Thr TVP Thr Gin Lys Leu Set Vat Pro Ser Gly Phe Set Val Thr Ala 
CCTGAAAAGCGGGGCTGGATCATCAACCCTCTGGGGGAAGAAGAGCCCTTTCCCGTGTGG 3120 
Pro Glu Lys Ar'g GIV Trp lie [le Asn Pro Leu GI y Glu Glu Glu Pro Phe Pro Va[ Trp 
ATGATGGTGGCCAGCC TGC TAC CCGCCATCTTGGTCTTCATCCTCATCTTCATGGAGACA 3180 
Met Met Val Ala Set Leu Leu Pro Ala Ile Leu Va[ Phe Ile Leu Ite Phe Met Giu Thr 
CAGATCACCACGCTGATCATCTCCAAAAAGGAGCGTATGCTGCAGAAGGGCTCTGGCTTT 32q0 
Gin lie Thr Thr Leu lee lie Ser Lys Lys Glu Arg Met Leu Gin Lys Gty Set GI y Phe 
CACCTGGACCTGCTGCTCATCGTGGCCATGGGTGGCATCTGTGCCCTCTTTGGCCTCCTC 3300 
His Leu Asp Leu Leu Leu tie VoI AIo Met Gly Gly Ile Cys AIo Leu Phe Gly Leu Leu 
TGGTTGGCTGCTGCTACCGTCCGCTCAGTCAC TCATGCCAACGCGCTCACTGTCATGAGC 3360 
Trp Leu Ala AIo Ala Thr VoI AP 9 Set VoI Thr His Ala ASh AIG Leu Thr Vol Met Sep 
AAGGCTG TGGCACCCGGGGATAAGCCCAAGATTCAGGAGGTC AAGGAGCAACGGGTGAC A 3q20 
Lys AIo Val Ala Pro Gly Asp Lys Pro Lys ]le Gin Glu Val Lys Glu Gin Arg Val Thr 
GGACTGCTGGTAGCCC TGCTCGTGGGACTC TCCTTAGTTATCGGGGATC TAC TCCGGCAA 3q80 
Gly Leu Leu VoI AIo Leu Leu Val Gly Leu Set Leu Val Ile Gly Asp Leu Leu Arg Gin 
ATCCCCTTAGC TGTGC TC TTTGGAATTTTCC TATACATGGGGGTGACCTCCC TAAACGGA 38q0 
[le Pro Leu AIo Val Leu Phe Gly Ile Phe Leu TyP Met GIy Val Thr Ser Leu Asn Gly 
ATCCAATTC TATGAGCGGC TACACC TGCTGC TCATGCCACCC AAACATCACCCAGATGTA 3600 
[le Gin Phe Tyr Glu Arg Leu His Leu Leu Leu Met Pro Pro Lys His His Pro Asp Val 
ATGTATGTAAAGAAGGTCCGCAC AATGCGCATGCACC TTTTC AAAGCCC TGC AGC TGCTC 3660 
Net Typ Val Lys Lys VQI Arx:j Thr Met Ar 9 Met His Leu Phe Lys AIo Leu Gin Leu Leu 
TGCCTGGCCCTGCTCTGGGCTGTCATGTCCACGGCGGCCTCCCTGGCCTTTCCATTCATC 3720 
6ys Leu Ala Leu Leu TPp Ala Val Met Sec ThP AIo AIo Sec Leu Ala Phe Pro Phe lie 
CTCATCCTCACAGTGCCACTGCGCATGGTGGTGCTCACCCGCATCTTCACAGAGCGAGAG 3780 
Leu Ile Leu Thr Vat Pro Leu Arg Met Vai Val Leu Thr Ar 9 Ile Phe Thr Glu APg Glu 
ATGAAATGTTTGGATGCTAATGAGGC AGAACC CG TGTTTGATGAGCGTGAGGGCGTGGAC 38q0 
Met Lys Cys Leu Asp AIQ Asn Glu Ala Gfu PPo Val Phe Asp GIu AP 9 Glu Gly Val Asp 
GAGTACAACGAGATGCCC ATGCC TGTG TAGC TGCAACCTGCAGGGACAGC TGAGGGCC C A 3900 
Glu Tyr Ash Glu Met Pro Met Pro Val • 
GTGGGCAGAGGGATTGGGGGCTGGTGGGATGGGCCTCCCCCTCCCCCTGCCTGTTTTTAT 3960 
TTAAGTGAATAATTTAAAGTCCCCT?CTCCCCACCCCCACAGTAAAGTGCTACAGCCCCC q020 
ACCAAAAAAAAAAAAAAAAAAA L~Oq2 
Fig 1 (continued). 
primers were also sequenced irectly. The complete 
AE2 sequence was compiled from a contig of 17 
different AE2 clones of varying lengths as well as 
the AE2 specific RT-PCR products from organ of 
Corti cDNA. Both, Sequencher and DNASTAR se- 
quence analysis programs were used for sequence 
alignments. 
2.2.3. RNA isolation 
RNA was isolated (Trizol, BRL) from gp organ of 
Corti (microdissected from six cochleae) as well as 
rat cochleae from which the bony labyrinth was re- 
moved. 
2.2.4. Protein extraction and Western blot analysis 
Tissue samples (stomach and cochleae), harvested 
from adult Hartley gp, were snap frozen in liquid 
nitrogen, pulverized in a Bio-Pulverizer and then im- 
mediately resuspended in cell lysis/gel oading buffer 
(50 mM Tris-C1, pH 6.8, 100 mM DTT, 2% SDS, 
10% glycerol). The homogenate was passed through 
26 gauge needle to shear genomic DNA, then re- 
solved on 1.0 mm thick 6% Tris-glycine mini-gel 
(Novex precast mini gel) via electrophoreses at 125 
V for 90 rain in Laemmli running buffer. Electropho- 
retic transfer to nitrocellulose membrane (Novex) 
was then performed at 25 V for 120 min using 
Tris-glycine transfer buffer (Tris base 12 mM, glycine 
96 mM, methanol 20%). The membrane was treated 
with 5% non-fat dry milk powder in 0.05% PBT at 
4°C overnight to block non-specific binding sites. 
The blot was then incubated with the affminty puri- 
fied anti-AE2 antibody [19,27,38] diluted 1/10000 in 
0.05% PBT at RT for 1 h. The blot was then washed 
6 A.N. Mhatre et al./Biochimica et Biophysica Acta 1414 (1998) 1-15 
> > > > >  
> > > > >  
o o o o o  
m m m m m  
N N N N M  
~ m m m ~g[~ 
M M N M 
N1 N N N N 
o o o o o c  
. . . . .  }1 
HHHHMH 
> > > >  
o ~ o o o c  
> > > > >  
> > > > ~  
o o o o o  
o o o o ~  
Z Z Z ~ Z  
> > > > > > 
> 
z ~  o o o o o  
N M N N N  ~ 
o o o o o  ~ 
> > > >  
> > > > !  
z z z z z  
N N N N M  
e N N N M  
mmmmm 
mmmmm 
e~ 
2 
8 
< 
e 
> > > > >  
> > > > >  
> > > > >  
> > > > > >  
N~t lNr l IN~. I  
< < < <  
o o o ~ o  
~> > > > > 
> > > > > 
I . . . . .  [ 
:> >:> > > 
0 
0 -g 
,=  
0 
0 I 
A.N. Mhatre et al. IBiochimica et Biophysica Acta 1414 (1998) 1-15 7 
i ~, : ~ : 
oooo I : : :o~ 
mmmm ~ ~ 
! - ! ~ - ! 
> > > > :> > > > :> .~ 
mm 
Uu 
M~ 
N~ 
m m co m m ~c~ 
I 
0 0 0  ~ 
m 
Z z ~  
[ ]  
m 
, r~  , , , 
I zzZZ~l  
> > > > >  
> > > > >  
Z Z Z Z ~  
~ H H H  I 
8 A.N. Mhatre et al. IBiochimica et Biophysica Acta 1414 (1998) 1-15 
in PBS followed by incubation with HRP conju- 
gated, goat anti-rabbit IgG (Amersham) for another 
1 h. After washing in PBS, the immunoblot was then 
developed using the ECL kit from Amersham. 
2.2.5. Tissue processing 
Animals were sacrificed with an intraperitoneal 
overdose of sodium pentobarbital (250 mg/kg) and 
bilateral thoracotomy. Temporal bones were har- 
vested from both sides of the head. Each bulla was 
opened using rongeurs to expose the cochlea. The 
stapes was removed and the cochlea fixed by perfu- 
sion of 4.5% paraformaldehyde through the round 
window. The cochlea was then removed from the 
remaining temporal bone and immersed in 4.0% par- 
aformaldehyde overnight at 4°C. After complete fix- 
ation, specimens were decalcified in 0.2 M EDTA/ 
1 x PBS/4.0% paraformaldehyde for 2-3 weeks, with 
at least three solution changes. Following decalcifi- 
cation, the specimens were placed in 0.9% saline, 
dehydrated through a graded alcohol series and 
then xylenes. Specimens were embedded in paraffin 
and sectioned at 6 ~tm on a microtome (Leica 
RM2035). 
2.2.6. Immunohistochemistry 
The paraffin-embedded cochlear sections were 
dewaxed, hydrated, blocked with 10% NHS, 0.1% 
Tween 20 in PBS and then hybridized overnight 
with rabbit antibody against mouse AE2 (1224- 
1237) [27] diluted 1:2000 to 1:5000. The sections 
were washed to remove unbound antibody and 
then hybridized with a secondary antibody (biotin- 
labeled anti-rabbit IgG monoclonal antibody). The 
bound label was then amplified using biotinylated 
tyramine and ABC reagent (Vector), as described 
by Adams [39], then developed with DAB. Specificity 
of this antibody for immunocytochemistry has been 
previously characterized in multiple tissues [19,27,38] 
and does not recognize AE3 in the conditions used. 
In the current experiments, antibody specificity was 
assessed by incubating the primary antibody in pres- 
ence of a competing peptide, 12 ~tg/ml, against which 
the antibody was raised. Sections were examined 
under low and high power magnification. 
2.2.7. In situ hybridization 
Paraffin-embedded cochlear sections were de- 
waxed, hydrated, incubated in 0.2 M HC1 for 10 
min, rinsed in PBS, digested with proteinase K (10 
gg/ml), fixed with 4% paraformaldehyde and then 
treated with 0.1 M triethanolamine and 0.25% acetic 
anhydride. The slides were rinsed in 2XSSC and 
then hybridized with in vitro transcribed, biotin la- 
beled gp AE2 cRNA probe, 10-50 ng/ml in hybrid- 
ization buffer (50% formamide, 4 × SSC, 5 × Den- 
hardt's solution and 200 gg/ml of yeast tRNA) 
overnight at 50°C in a sealed chamber. The sections 
were washed under high stringency (50% formamide/ 
2×SSC at 50°C) to remove unbound label. The 
bound label was then amplified using biotinylated 
tyramine and ABC reagent (Vector, Burlingame, 
CA), as described by Adams [39], then developed 
with DAB. The AE2 cRNA probe used in in situ 
hybridization is transcribed from XbaI linearized 
pGEM7Z-AE (2169-3010) via SP6 polymerase. 
The sense probe was transcribed from BamHI line- 
arized template with T7 RNA polymerase. 
pGEM7Z-AE (2169-3010) was constructed by ligat- 
ing an 841 bp AE2 fragment, amplified from a 
pSPORTI-AE2 clone using primers (P1, ACTGGT- 
CAAGATCTTCCA; P2, GTCACCCCCATGTAT) 
spanning nucleotides (nt) 2169-3010 of the gp AE2 
cDNA, into the SmaI site within the pGEM7Z poly- 
linker. 
3. Results 
3.1. Relative abundance of AE cDNAs in the gp 
organ of Corti cDNA library 
A total of 37 'positive' clones were purified. Of 
these, 23 were selected for sequence analysis after 
elimination of duplicates, determined from insert 
size and restriction fingerprints. These positives 
were sequenced from both the 5' and 3' ends of 
the insert. The nt sequence of the positive clones 
was compared (aligned) with sequence of AE1, 
AE2 and AE3 to determine their identity. Of the 
23 clones 17 were identified as AE2 clones, ranging 
in size from 4.0 to 0.7 kb, while four were AE3 
clones of sizes 2.7 to 1.0 kb. No AE1 cDNA clone 
was identified, and no cDNAs encoding novel AE 
genes were identified by the screen. AE2 cDNAs 
were chosen for further study. 
A.N. Mhatre et aL /Biochimica et Biophysica Acta 1414 (1998) 1-15 9 
3.2. Sequence analysis of gp cochlear AE2 
The longest AE2 clone sequenced was nearly 4.0 
kb in size. This clone was sequenced in both direc- 
tions and integrated with partial 5' sequences from 
16 additional AE2 clones of varying size and AE2 
specific RT-PCR products from organ of Corti 
cDNA. The compiled AE2 cDNA sequence and its 
encoded polypeptide sequence are shown in Fig. 1. 
The complete cDNA sequence is 3888 bp in length, 
including 150 bp of 5' untranslated sequence and an 
open reading frame (ORF) of 3717 bp that extends 
from nt 151 to 3870. The ORF encodes the AE2 poly- 
peptide consisting of 1238 amino acids and with cal- 
culated apoprotein molecular weight of 137 kDa. 
The gp AE2 coding sequence was further charac- 
terized by alignment with AE2 polypeptides from 
other species, including human, mouse, rat and rab- 
bit, as well as the gp AE2c~ sequence [33]. The se- 
quence identity of gp AE2c~ with its orthologs from 
other species ranged from 90 to 92°/,,. The rat and the 
mouse AE2 sequence displayed the highest degree of 
sequence identity (97%) between species. The gp 
AE2~ sequence differs from the conventional gp 
AE2 sequence by the 83 bp deletion spanning nt 
2158 2240 of gp AE2. In addition, the current gp 
AE2 sequence differs in 35 amino acid residues 
from the sequence presented by Negrini et al. (Gene- 
Bank accession o. U20524) [33]. Among those 35 
amino acid differences, 23 represent residues for 
which the present gp AE2 sequence shares identity 
with human, mouse, rat and rabbit sequences, and 
four represent residues identical to those of three of 
the four other species. These differences between gp 
AE2 and AE2ct are illustrated in Fig. 2. 
We did not find AE2~ among any of the AE2 
cDNA clones picked from the organ of Corti 
cDNA library. Pooled cDNA from the organ of Cor- 
ti cDNA library as well as organ of Corti cDNA was 
also characterized for presence of clones containing 
the AE2~ transcript via PCR analysis using primers 
flanking the 83 bp deletion/splice site reported within 
the variant by Negrini et al. [33]. A single uniform 
product was consistently obtained from this reaction 
corresponding to the length of gp AE2, but no short- 
er fragment corresponding to the gp AE2~ sequence 
was ever observed (data not shown). 
Also included amongst the 'positives' from the 
cDNA library, identified as AE2 clones, were a single 
clone with an insertion of 133 bases and a single 
clone with a deletion of 155 bases (distinct from 
the AE2c~ variant). However, these alterations were 
not detected by RT-PCR analysis in the organ of 
Corti cDNA or in cDNA from brain and kidney, 
and were concluded to be library artifacts. 
3.3. Western blot analysis of AE2 expression in the 
gp cochlea 
AE2 expression within the cochlea was also charac- 
terized by immunoblot analysis, as illustrated in Fig. 3. 
The anti-AE2 antibody revealed a single immuno- 
reactive band of Mr 180 kDa in gp cochlear homo- 
genate. Stomach homogenate revealed two distinc~ 
bands of Mr 165 and 125 kDa, consistent with pre- 
vious results. The immunoreactive bands from both 
the cochlear and stomach omogenates were absent 
in presence of synthetic peptide antigen correspond- 
ing to mouse AE2 amino acid residues 1224-1237. 
'?~i!i 
~i!iii 
- -  180 kDa 
- -  165 kDa 
- -  125 kDa 
C S C S 
ant i -AE2  Ab  + + + + 
pept ide  + + 
c - cochlea; s - stomach 
Fig. 3. Western blot analysis of AE2 expression i  the gp coch- 
lea. Homogenate from gp tissues including cochleae (c) was re- 
solved on a 6% SDS-PAGE, transferred to nitrocellulose mem- 
brane. The Western blot was probed with anti-AE2 Ab and 
then developed using the ECL kit from Amersham. A single 
immunoreactive band, M,. 180 kDa, is observed in the cochlear 
homogenate while two major bands, Mr 165 and 125 kDa, are 
seen in the stomach (s) homogenate. The immunoreactive bands 
are eliminated in presence ofa synthetic immunogenic peptide. 
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Fig. 4. Immunolocalization f AE2 polypeptide in the guinea pig cochlea. Radial sections of gp cochlea were hybridized with anti- 
AE2 antibody and then developed using biotin labeled anti rabbit 2 ° antibody, biotin amplification system and then stained with 
DAB. Several regions surrounding the cochlear duct (CD) are immunoreactive with the anti AE2 antibody (a). These include the 
superior half of the spiral ligament (SL), the interdental cells in the spiral limbus (sl), several cell types within the organ of Corti and 
the vasculature. Region surrounding the cochlear duct (CD), including the sensory cells within organ of Corti (arrow), is unstained 
when the antibody is hybridized in presence of competitive peptide (b). A higher power view of the organ of Corti from (a) reveals 
weak AE2 immunoreactivity n or near the OHC (c), while the cell bodies of the spiral ganglia are unstained (d). 
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Fig. 4 (continued). 
3.4. In situ expression analysis of AE2 in the gp 
cochlea 
Localization of AE2 expression within the gp 
cochlea was determined via immunohistochemistry 
and in situ hybridization. Cochlear sections tained 
with the anti-mouse AE2 antibody showed immuno- 
staining signal in several regions as illustrated in Fig. 
4a. The immunoreactive regions include the superior 
half of the spiral ligament (the lateral wall of the 
cochlear duct), the interdental cells of the spiral lim- 
bus, the hinge region between the spiral ligament and 
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the organ of Corti, within the organ of Corti, and in 
vascular smooth muscle. Stained red cells as ob- 
served in Fig. 4a represent crossreactivity of the anti- 
body with AE1. Immunostaining was operationally 
specific, as defined by abolition of staining in the 
presence of excess peptide antigen (Fig. 4b). A higher 
magnification view of the organ of Corti from Fig. 
3a shows light staining of several cell types within the 
organ of Corti-Hensen cells, the Deiters cells, the 
outer phalangeal cells, as well as adjacent to the out- 
er hair cells (Fig. 4c). The DAB signal intensity and 
the magnification, however, did not suffice to permit 
definitive localization of immunoreactivity within the 
OHC. A prominent tissue type unstained by the AE2 
antibodies i the spiral ganglion (Fig. 4d). Absence of 
signal in the neuronal bodies contrasts with immu- 
noreactivity (AE1 crossreactivity) of blood cells and 
the smooth muscle cells of the vasculature that tra- 
verses the spiral ganglion. 
Immunohistochemical analysis of AE2 expression 
was supplemented with in situ hybridization. Similar 
to immunohistochemical detection, the antisense 
AE2 cRNA probe localized the AE2 transcript in 
the superior half of the spiral ligament as well as in 
the interdental cells of the spiral limbus (Fig. 5). The 
additional sites that are stained in the immunohisto- 
chemistry assay may reflect differing sensitivities of 
the two assays in this tissue preparation. 
4. Discussion 
Study of the role of anion exchangers within the 
OHC was initiated by characterizing expression of its 
family members within the organ of Corti cDNA 
library, cDNAs encoding two members of the AE 
gene family, AE2 and AE3 were cloned from this 
library, and were present in a 4:1 ratio. Neither, 
AE1 nor any other AE homologs were detected 
through the screen. Subsequent characterization fo- 
cused on the more abundant AE2 cDNAs. 
Complete gp AE2 coding sequence was obtained 
and compared with its orthologs from other species. 
The sequence alignment analysis did not identify 
unique or substantially altered sequence motifs with- 
in the gp AE2 relative to its orthologs from other 
species. Thus the AE2 clones obtained from the or- 
gan of Corti are representative of the predominant 
Fig. 5. In situ AE2 RNA expression within the guinea pig cochlea. Radial sections of gp cochlea were hybridized with biotin labeled 
antisense gp AE2 RNA, developed using biotin amplification system and then stained with DAB. The superior half of the spiral liga- 
ment lining the cochlear duct and the interdental cells in the spiral limbus display AE2 hybridization signal. 
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form of AE2 that has been cloned from other tissue 
types, including kidney and colon, in different species 
[26,35,36]. 
The nt sequence of gp AE2 was also compared 
with gp AE2~, the AE2 isoform [33] (data not 
shown). In addition to revealing the codons that 
underlie the amino acid differences, the alignment 
of the two sequences also identified the nt that flank 
the putative 'splice' junction in the AE2~, 'CA' on 
the 5' side and 'GGI' on the 3' side. These flanking 
nt differ from the invariant consensus nt pairs found 
at splice junctions, 'AG' on the 5' side and 'GT' on 
the 3' side. Although the AE2~ isoform was isolated 
from the same cDNA library as that used in the 
present experiments, a thorough search of all our 
isolated AE2 clones whose 5' ends extended beyond 
the AE2~ splice point [33] did not reveal presence of 
the AE2a isoform. Interestingly, Abs raised against 
the AE2a yield a protein band of the size expected 
from the length of its polypeptide [33,34], indicating 
absence of post-translational modifications such as 
N-glycosylation present in other cloned AE2 poly- 
peptides. [27,36]. 
Identification and sequence analysis of gp AE2 
cDNA within the gp organ of Corti cDNA library 
was supplemented with characterization of the gp 
cochlear homogenate for AE2 polypeptide xpres- 
sion. Immunoblot analysis using an anti-AE2 Ab, 
raised against he C-terminus peptide [27] identified 
a single immunoreactive band of Mr 180 kDa Immu- 
noreactivity of this protein band against the anti- 
AE2 Ab was competed by synthetic peptide antigen. 
The 180 kDa polypeptide band identified by the anti- 
AE2 Ab is larger than the 165 and 125 kDa AE2 
polypeptides detected in gp stomach homogenate, 
also competed by synthetic peptide antigen. The 
165 kDa band corresponds to with the observed 
size for rat and murine AE2 [27,36]. The predicted 
molecular weight of gp AE2 is 137 kDa. Thus, the 
increased band size observed on SDS-PAGE likely 
reflects N-glycosylation of AE2 [28]. The 125 kDa 
band represents either an N-terminal proteolytic 
product, an immature glycosylation product, or 
may represent the AE2c isoform [24]. 
The AE2 Ab used in this study has also yielded an 
AE2 immunoreactive smear extending from 165 up- 
ward to 185 kDa in the rat aorta and a 180/185 kDa 
band in rat kidney (Hailer and Alper, unpublished 
data). Polyclonal Ab to a conserved C-terminal pep- 
tide was shown to recognize a single major 185 kDa 
band in a immunoblot of a membrane fraction from 
rabbit stomach. Similarly, a 180 kDa band was iden- 
tified in immunoblot of membrane fraction from hu- 
man kidney probed with a polyclonal Ab raised 
against a C-terminal fragment of human AE1 [40]. 
Neither of these immunoreactive bands identified in 
the rabbit stomach or the human kidney were de- 
tected when probed with AEl-specific Abs directed 
towards the variant N-terminus. 
Thus, the presence of a single AE2-immunoreac- 
tive protein species within the cochlear homogenate, 
its operational immunospecificity, and the corre- 
spondence of its size with those previously reported 
for AE2 in several tissues supports its identity as 
cochlear AE2. 
Immunohistochemical analysis and in situ hybrid- 
ization identified two distinct regions of AE2 expres- 
sion within the gp cochlea. These included the supe- 
rior half of the lateral wall of the cochlear duct and 
the interdentat cells within the spiral limbus. These 
regions yielded positive signal for both in-situ hy- 
bridization and immunohistochemical assays. Curi- 
ously, neither of these regions interfaces directly 
with a lumen. One of the stained regions, the spiral 
ligament, is located underneath the stria vascularis 
that lines the cochlear duct, though the strial cells 
themselves were unstained. The interdental cells 
within the spiral limbus, the other stained region, 
are underneath a portion of the tectorial membrane 
that reaches out across the organ of Corti. The cells 
bordering the inner sulcus, adjacent to the interden- 
tal cells and directly in contact with the endolymph, 
were unstained. The presence of AE2 polypeptide 
and mRNA within the cells of the spiral ligament 
(superior half/peripheral region) and the interdental 
cells strongly suggests that they express CI/HCO3 
exchange function. 
The immunohistochemical assay also yielded a sig- 
nal in several other sites that were absent in the in 
situ hybridization assay. These included the hinge 
region between the spiral ligament and the organ of 
Corti as well as the blood cells and smooth muscle of 
the vasculature. Several cell types within the organ of 
Corti were stained weakly in the immunohistochem- 
ical assay, but not via in situ hybridization. These 
cell types include the Deiters cells, phalangeal cells 
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and the pillar cells that surround the inner and outer 
hair cells. The partially overlapping staining patterns 
of the two assays may reflect differences in their spe- 
cificity and/or sensitivity, or regional differences in 
relative abundance of AE2 mRNA and protein. 
The peptide sequence against which the AE2 Ab 
was raised, corresponding to mouse AE2 amino acid 
residues 1224-1237, is fully conserved in the rat and 
displays over 90% identity (13/14) in both human 
and gp AE2 (the lone difference is substitution of 
C1225 with R, Fig. 2). The conservation of this anti- 
gen sequence is reduced to 64 and 71% with cross- 
reactive mouse and rat AE1, respectively. The AE2 
peptide antigen sequence is less well conserved in 
AE3 and the anti-AE2 antibody displays marginal 
or no crossreactivity with overexpressed recombinant 
AE3 and no crossreactivity with native AE3 in stom- 
ach, heart, and brain (Alper and Stuart-Tilley, un- 
published results). Accordingly, the neurons of the 
spiral ganglion of the cochlea are unstained, consis- 
tent not only with absence of AE2 expression, but 
with likely expression of AE3. 
The relative specificity or crossreactivity of the 
AE2 cRNA probe used in the in situ hybridization 
assay may be similarly assessed by comparative se- 
quence analysis with its homologs. The cRNA probe 
used in the assay is 841 bp long derived from se- 
quence within the 3'-half of the gp AE2 cDNA. 
This sequence corresponds to amino acids 838-1133 
within the mouse AE2. This probe, although located 
within the relatively conserved C-terminus, does not 
overlap the peptide sequence to which the AE2 anti- 
body was raised. If the motor protein, inferred to be 
an abundantly expressed transmembrane protein 
(one million copies per OHC), is AE2, then both in 
situ hybridization and immunohistochemistry should 
have yielded an unambiguous signal in OHC. This 
was not found thus negating a role for AE2 in medi- 
ating OHC electromotility. 
The human genes encoding AE1, AE2 and AE3 
have been mapped. AE1 to 17q21~122, AE2 to 
7q35-q36 [41], and AE3 to 2q36. Mutations in hu- 
man AE1 have been linked to 25% of dominant he- 
reditary spherocytosis [21,42], and to some forms of 
dominant distal renal tubular acidosis without hear- 
ing impairment [22,23]. Human mutations within 
AE2 or AE3 have not been reported. Although the 
presence of AE2 anion exchanger within the inner 
ear implies a physiological role in ionic homeostasis 
of the cochlea, no hereditary syndromic or non-syn- 
dromic hearing loss loci map within the chromoso- 
mal regions of the AE anion exchanger genes [43]. 
In summary, we have cloned the AE2 cDNA from 
gp organ of corti, detected AE2 polypeptide by im- 
munoblot of gp cochlea and localized AE2 mRNA 
and AE2 polypeptide in the gp cochlea. Though AE2 
is expressed in gp cochlea, it was not detected in hair 
cells. Thus, the present results suggest that AE2 may 
not be considered as a candidate motor protein of 
the outer hair cells. 
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